6,326 results match your criteria Pancreatic Adenocarcinoma Imaging


Concurrent Pancreatic Metastasis From Lung Adenocarcinoma and Primary Cholangiocarcinoma on FDG PET/CT Imaging.

Clin Nucl Med 2019 Feb 8. Epub 2019 Feb 8.

From the Department of Nuclear Medicine, Beijing Friendship Hospital of Capital Medical University, Beijing, China.

A 67-year-old man with a history of left upper lobe resection of poorly differentiated adenocarcinoma 1 year ago underwent FDG PET/CT for restaging. The images demonstrated a round cystic lesion with peripheral FDG uptake and centrally photopenic region. Additional focus of increased activity was detected in the left lobe of the liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002496DOI Listing
February 2019

Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer.

HPB (Oxford) 2019 Feb 2. Epub 2019 Feb 2.

Department of Surgery, Stanford University, Stanford, CA, USA. Electronic address:

Background: Although most patients with PDAC experience distant failure after resection, a significant portion still present with local recurrence. Intraoperative fluorescent imaging can potentially facilitate the visualization of involved peritumoral LNs and guide the locoregional extent of nodal dissection. Here, the efficacy of targeted intraoperative fluorescent imaging was examined in the detection of metastatic lymph nodes (LNs) during resection of pancreatic ductal adenocarcinoma (PDAC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hpb.2018.11.008DOI Listing
February 2019

Early Detection of Pancreatic Cancer: Opportunities and Challenges.

Gastroenterology 2019 Feb 2. Epub 2019 Feb 2.

Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Sheikh Ahmed Center for Pancreatic Cancer Research, University of Texas MD Anderson Cancer Center, Houston, Texas.

The vast majority of patients with pancreatic ductal adenocarcinoma (PDAC) presents with symptomatic, surgically unresectable disease. While the goal of early detection of PDAC is laudable, and likely to result in significant improvement in overall survival, the relatively low prevalence of PDAC renders general population screening infeasible. The challenges of early detection include identification of at-risk individuals in the general population who would benefit from longitudinal surveillance programs, and appropriate biomarker and imaging-based modalities utilized for PDAC surveillance in such cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2019.01.259DOI Listing
February 2019
1 Read

Evaluation of intracavitary carboplatin chemotherapy for treatment of pleural carcinomatosis in cats: a retrospective study of eight cases.

J Feline Med Surg 2019 Feb 5:1098612X19826401. Epub 2019 Feb 5.

1 ONCOVET, Veterinary Clinic of Referrals, Villeneuve d'Ascq, France.

Objectives: The aim of this study was to evaluate the benefit of intracavitary carboplatin chemotherapy in cats with malignant pleural effusion of epithelial origin.

Methods: The medical records of cats with a cytological diagnosis of neoplastic pleural effusion of epithelial origin were reviewed at three referral institutions between January 2013 and June 2018. Only cats treated with intracavitary carboplatin chemotherapy were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1098612X19826401DOI Listing
February 2019
1 Read

Prognostic evaluation of pancreatic ductal adenocarcinoma: Associations between molecular biomarkers and CT imaging findings.

Pancreatology 2019 Jan 24. Epub 2019 Jan 24.

Department of Radiology, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan.

Objectives: To investigate association between molecular biomarkers and computed tomography (CT) imaging findings in patients with pancreatic ductal adenocarcinoma (PDAC).

Methods: Fifty-three consecutive patients with PDAC (34 men and 19 women; mean age, 70.6 ± 8. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pan.2019.01.016DOI Listing
January 2019

Recurrent pancreatic adenocarcinoma depicted by F-fluciclovine PET/CT imaging.

Authors:
B D Nguyen T I Ocal

Rev Esp Med Nucl Imagen Mol 2019 Feb 1. Epub 2019 Feb 1.

Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, Arizona, Estados Unidos.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.remn.2018.10.003DOI Listing
February 2019

Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography.

PLoS One 2019 1;14(2):e0211566. Epub 2019 Feb 1.

Department of Radiology, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.

Hypovascular pancreatic neuroendocrine tumors (hypo-PNETs) are often misdiagnosed as pancreatic ductal adenocarcinoma (PDAC). However, the treatment options and prognosis of PNETs and PDAC are substantially different. This retrospective study differentiated hypo-PNETs from PDAC using contrast-enhanced CT (CE-CT). Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211566PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358067PMC
February 2019

Uncommon Intraluminal Tumors of the Gallbladder and Biliary Tract: Spectrum of Imaging Appearances.

Radiographics 2019 Feb 1:180164. Epub 2019 Feb 1.

From the Departments of Radiology (A.C., C.L.V., P.N., N.A.H., V.Y., F.H.M.) and Pathology (A.J.B., G.Y.Y.), Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 676 N St. Clair St, Suite 800, Chicago, IL 60611; Department of Radiology, Emory University School of Medicine, Atlanta, Ga (P.K.M.); and Department of Radiology, Mayo Clinic, Scottsdale, Ariz (C.O.M.).

Intraluminal pathologic conditions of the bile ducts and gallbladder are common, most frequently consisting of calculi and adenocarcinoma. In recent years, intraductal papillary neoplasm of the bile ducts (IPN-B), which is analogous to intraductal papillary mucinous neoplasm of the pancreas, has been recognized as a distinct pathologic entity and a precursor lesion to adenocarcinoma of the bile ducts. Intraductal tubulopapillary neoplasm (ITPN) of the bile duct was subsequently described as a distinct pathologic entity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/rg.2019180164DOI Listing
February 2019
1 Read

Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues.

Dig Dis 2019 Jan 30:1-10. Epub 2019 Jan 30.

Consultant, Department of Gastrointestinal Surgery, Lilavati Hospital and Research Center, Mumbai, India.

Background: The incidence of pancreatic adenocarcinoma (PDAC) in patients with chronic pancreatitis (CP) is as high as 5%. It is a commonly encountered diagnostic challenge in patients with CP on long-term follow-up.

Summary: This review consolidates the existing literature on assessment of PDAC in background of CP, its evaluation through the available investigations, surgical management, and prognostication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496507DOI Listing
January 2019
1 Read

Diffusion kurtosis imaging and conventional diffusion weighted imaging to assess electrochemotherapy response in locally advanced pancreatic cancer.

Radiol Oncol 2019 Jan 19. Epub 2019 Jan 19.

Division of Hepatobiliary Surgical Oncology, Unit, Instituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italia.

Background The aim of the study was to evaluate diagnostic performance of functional parameters derived by conventional mono-exponential approach of diffusion weighted imaging (DWI) and by diffusion kurtosis imaging (DKI) in the assessment of pancreatic tumours treated with electrochemotherapy (ECT). Patients and methods Twenty-one consecutive patients with locally advanced pancreatic adenocarcinoma subjected to ECT were enrolled in a clinical approved trial. Among twenty-one enrolled patients, 13/21 (61. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/raon-2019-0004DOI Listing
January 2019

Brain metastasis in pancreatic cancer: Two case reports.

Medicine (Baltimore) 2019 Jan;98(4):e14227

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo.

Rationale: Brain metastases are extremely rare for patients with pancreatic adenocarcinoma due to the poor prognoses. In the present study, we reported 2 cases of pancreatic adenocarcinoma with brain metastases.

Patient Concerns: The 1st patient was diagnosed asymptomatic brain metastasis by a follow-up brain magnetic resonance imaging (MRI) due to a medical history of subarachnoid hemorrhage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014227DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358345PMC
January 2019

DWI of Pancreatic Ductal Adenocarcinoma: A Pilot Study to Estimate the Correlation With Metastatic Disease Potential and Overall Survival.

AJR Am J Roentgenol 2019 Feb 4;212(2):323-331. Epub 2018 Dec 4.

1 Department of Radiology, Division of Abdominal Imaging, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Ansin 235, Boston, MA 02115.

Objective: The purpose of this study is to analyze the relationship between the apparent diffusion coefficient (ADC) of pancreatic ductal adenocarcinoma (PDAC) and the presence or development of metastasis and overall survival (OS).

Materials And Methods: Of 290 consecutive patients with histopathologically proven PDAC from January 2013 to December 2014, staging DWI was performed for 124 patients. Image quality was adequate in 112 studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.18.20017DOI Listing
February 2019

"Shades of Gray" in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer.

Crit Rev Oncol Hematol 2019 Jan 2;133:17-24. Epub 2018 Nov 2.

Medical Oncology, Candiolo Cancer Institute, FPO, IRCCS, Department of Oncology University of Torino, Italy.

Pancreatic ductal adenocarcinoma is one of the leading causes of cancer-related deaths and, currently, surgery is the only curative treatment. Patients with borderline resectable pancreatic cancer (BRPC) can benefit from a multidisciplinary approach and R0 resection, and can achieve the same outcome as resectable patients treated with upfront surgery. However, the definition of BRPC changes according to different classifications with a heterogeneous distribution of patients, and it is thus difficult to compare clinical evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.10.009DOI Listing
January 2019

Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition.

Transl Res 2019 Jan 4. Epub 2019 Jan 4.

Departments of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies and has one of the worst prognoses leading to a meager 5-year survival rate of ∼8%. Chemotherapy has had limited success in extending the life span of patients with advanced PDAC due to poor tumor perfusion and hypoxia-induced resistance. Hypoxia reprograms the gene expression profile and upregulates the expression of multiple genes including heme oxygenase-1 (HO-1), which provide survival advantage to PDAC cells. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19315244193000
Publisher Site
http://dx.doi.org/10.1016/j.trsl.2018.12.008DOI Listing
January 2019
5 Reads

Pancreatic Head Carcinoma-Implications and Correlations in a Romanian Population.

Curr Health Sci J 2018 Jul-Sep;44(3):231-234. Epub 2018 Jul 15.

Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, Romania.

Introduction: Pancreatic cancers are often an aggressive type of malignancy, with a 5-year survival rate estimated at around 5%. The main purpose of our study was to determine whether or not tumor dimensions influence the presence of jaundice and the diameters of the CBD and Wirsung duct.

Material And Methods: The study group included 32 patients (19 males, 13 females) diagnosed with various histological types of pancreatic head cancers who were hospitalized in the Surgery Department of the County Clinical Emergency Hospital of Craiova during 2016-2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12865/CHSJ.44.03.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311222PMC
July 2018
1 Read

Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?

J Surg Oncol 2019 Jan 12. Epub 2019 Jan 12.

Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana.

Background: Breast cancer (BRCA) mutations account for the highest proportion of hereditary causes of pancreatic ductal adenocarcinoma (PDAC). Screening is currently recommended only for patients with one first-degree relative or two family members with PDAC. We hypothesized that screening all BRCA1/2 patients would identify a higher rate of pancreatic abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25376DOI Listing
January 2019
1 Read

Prospective comparison of (4S)-4-(3-F-fluoropropyl)-L-glutamate versus F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocarcinoma: a proof-of-concept study.

Eur J Nucl Med Mol Imaging 2019 Jan 11. Epub 2019 Jan 11.

Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, 7 Chung-Shan South Rd., Taipei, 10002, Taiwan, Republic of China.

Purpose: (4S)-4-(3-F-Fluoropropyl)-L-glutamate (FSPG) positron emission tomography (PET) reflects system x transporter (xCT) expression. FSPG PET has been used to detect brain, lung, breast and liver cancer with only modest success. There is no report on the use of FSPG PET in pancreatic ductal adenocarcinoma (PDAC), presumably because of normal xCT expression in the pancreas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4251-5DOI Listing
January 2019
2 Reads

Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy.

J Pancreat Cancer 2018 15;4(1):95-99. Epub 2018 Nov 15.

Department of Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.

Euglycemic diabetic ketoacidosis (euDKA) is a potential side effect associated with inhibitors of the sodium-glucose cotransporter 2 (SGLT-2). This effect is most often recognized during physiologic stress (i.e. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/pancan.2018.0016
Publisher Site
http://dx.doi.org/10.1089/pancan.2018.0016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319615PMC
November 2018
10 Reads

Duodenal Adenocarcinoma in a Patient with Partial Intestinal Malrotation.

J Pancreat Cancer 2018 1;4(1):30-32. Epub 2018 Jun 1.

Department of Surgery, Jefferson Pancreas, Biliary, and Related Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

Small bowel cancers, specifically duodenal cancer, occur at very low rates but require aggressive surgical resection when diagnosed. An even rarer finding is the presence of intestinal malrotation. We present the unique case of a patient with both duodenal cancer and partial intestinal malrotation undergoing pancreaticoduodenectomy. Read More

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/pancan.2018.0005
Publisher Site
http://dx.doi.org/10.1089/pancan.2018.0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145535PMC
June 2018
2 Reads

Long term oncological outcome of laparoscopic techniques in pancreatic cancer.

World J Gastrointest Endosc 2018 Dec;10(12):383-391

the Intervention Centre and Department of Hepato-Pancreatico-Biliary Surgery, Institute of Clinical Medicine, Faculty of Medicine, Oslo University Hospital, Oslo N-0424, Norway.

The laparoscopic technique in distal pancreatic resection (LDP) has been widely accepted, and outcome data support the hypothesis that survival is improved, partly due to improved postoperative safety and recovery, thus optimizing treatment with adjuvant chemotherapy. But laparoscopic pancreaticoduodenectomy (LPD or Whipple-procedures) has spread more slowly, due to the complexity of the procedure. Surgical safety has been a problem in hospitals with low patient volume, resulting in raised postoperative mortality, requiring careful monitoring of outcome during the surgical learning curve. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4253/wjge.v10.i12.383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323502PMC
December 2018

Neoadjuvant Treatment for Pancreatic Cancer.

Semin Oncol 2018 Dec 28. Epub 2018 Dec 28.

The Division of Medical Oncology, Columbia University Medical Center, New York, NY.

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality rates. Currently, cure can only be achieved through resection, however the vast majority of patients present with advanced disease for which upfront surgery is not an option. In an effort to improve surgical candidacy, neoadjuvant chemotherapy, with or without radiation therapy, is often used in an effort to downstage borderline resectable and locally advanced tumors, and some argue for its use even in patients with resectable tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2018.12.002DOI Listing
December 2018

Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.

PLoS One 2019 10;14(1):e0210178. Epub 2019 Jan 10.

Department of Radioisotope Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Purpose: Pancreatic cancer is the 4th most common cause of cancer death in Japan and exhibits a 5-year overall survival rate of approximately 7%. The accurate diagnosis of pancreatic cancer is important for determining the optimal management strategy. Fludeoxyglucose-positron emission tomography (FDG PET) integrated with computed tomography (18F-FDG PET/CT) has emerged as a powerful imaging tool for detecting and evaluating various cancers, and it is used for staging, detecting local recurrence and distant metastasis, measuring therapeutic effects, and predicting prognosis in pancreatic cancer patients. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210178PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328180PMC
January 2019

Comparative Accuracy of Tumor Size Assessment and Stage Analysis by Imaging Modalities Versus Gross Examination for Pancreatic Ductal Adenocarcinoma.

Pancreas 2019 Feb;48(2):223-227

From the Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.

Objectives: Tumor size has been shown to be a strong predictor of patient survival in pancreatic ductal adenocarcinoma (PDAC). The aims of this study were to assess the consistency of preoperative imaging and gross examination for PDAC tumor size measurement and to evaluate the impact on T and overall tumor staging when size measurements by imaging and gross examination were different.

Methods: Patients diagnosed with PDAC who underwent pancreaticoduodenectomy or distal pancreatectomy from 2007 to 2017 were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00006676-201902000-0001
Publisher Site
http://dx.doi.org/10.1097/MPA.0000000000001233DOI Listing
February 2019
4 Reads

[Detection of small pancreatic cancer during surveillance of the main pancreatic duct stenosis].

Nihon Shokakibyo Gakkai Zasshi 2019 ;116(1):99-108

Department of Gastroenterology, Sendai City Medical Center.

An 83-year-old man with main pancreatic duct (MPD) stenosis in the pancreatic body had undergone surveillance with semiannual imaging studies for 3 years. During surveillance, magnetic resonance cholangiopancreatography revealed gradual enlargement of a small cyst near the MPD stenosis and contrast-enhanced computed tomography revealed locally progressive atrophic parenchyma in the pancreatic body. On endoscopic retrograde pancreatography, the MPD stenosis was more severe than it had been at diagnosis 3 years earlier. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11405/nisshoshi.116.99DOI Listing
January 2019

A Diagnostically Challenging Case of Autoimmune Pancreatitis Due to Contamination of the Pathological Specimen with Early Gastric Cancer.

Intern Med 2019 Jan 10. Epub 2019 Jan 10.

Department of Gastroenterology, Saitama Medical Center, Jichi Medical University, Japan.

A 73-year-old man with worsened diabetes underwent abdominal computed tomography and was diagnosed with localized enlargement of the pancreatic tail. Based on the suspicion of autoimmune pancreatitis, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was performed. A cytologic examination showed findings suggestive of adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2218-18DOI Listing
January 2019
1 Read

Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach.

AJR Am J Roentgenol 2019 Jan 8:1-6. Epub 2019 Jan 8.

1 Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St., Ste 1010, Boston, MA 02114.

Objective: The objective of our study was to test for the possibility that published malignancy risks for side-branch intraductal papillary mucinous neoplasms (IPMNs) are overestimates, likely due to verification bias.

Materials And Methods: We tested for possible verification bias using simulation modeling techniques. First, in age-defined hypothetical cohorts of 10 million persons, we projected the frequency of pancreatic ductal adenocarcinoma (PDAC) arising from side-branch IPMNs over 5 years using published estimates of their prevalence (4. Read More

View Article

Download full-text PDF

Source
https://www.ajronline.org/doi/10.2214/AJR.18.20180
Publisher Site
http://dx.doi.org/10.2214/AJR.18.20180DOI Listing
January 2019
4 Reads

Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma.

Eur J Radiol 2019 Jan 11;110:66-73. Epub 2018 Apr 11.

Department of Abdominal Surgery, A.V. Vishnevsky Institute of Surgery, Moscow, Russia.

Purpose: The purpose of our study was to determine contrast-enhanced MDCT features to differentiate nonhypervascular pancreatic neuroendocrine tumors (PNETs) from pancreatic ductal adenocarcinomas (PDACs).

Methods: and materials: We included 74 patients with PNETs and 80 patients with PDACs who underwent preoperative MDCT. Two radiologists evaluated the morphologic characteristic and enhancement patterns of the tumors. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0720048X183012
Publisher Site
http://dx.doi.org/10.1016/j.ejrad.2018.04.006DOI Listing
January 2019
9 Reads

Gd-EOB-DTPA dynamic contrast-enhanced magnetic resonance imaging is more effective than enhanced 64-slice CT for the detection of small lesions in patients with hepatocellular carcinoma.

Medicine (Baltimore) 2018 Dec;97(52):e13964

Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.

This study aimed to compare the sensitivity and accuracy for the detection of small lesions in patients with hepatocellular carcinoma (HCC) using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and 64-slice computed tomography (CT) enhanced scanning, and to evaluate the necessity to perform MRI in patients diagnosed with HCC by CT.The clinical data from 209 patients with HCC diagnosed prior to surgery in the Affiliated Hospital of Guilin Medical University, China were retrospectively analyzed. The 64-slice dynamic contrast-enhanced multi-detector CT (MDCT) and 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013964DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314721PMC
December 2018
1 Read

Chinese expert consensus on radioactive I seeds interstitial implantation brachytherapy for pancreatic cancer.

J Cancer Res Ther 2018 ;14(7):1455-1462

Department of Medical Imaging, Minimally Invasive Interventional Center, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Pancreatic cancer, also known as exocrine pancreatic carcinoma or pancreatic ductal adenocarcinoma, is one of the most challenging tumor entities worldwide, which is characterized as a highly aggressive disease with dismal overall prognosis. Treatment options for patients with locally advanced pancreatic cancer include surgery, chemotherapy, and radiotherapy. In many cases, surgical resection is not possible due to the advanced stage at diagnosis and poor responses to current treatments, therefore, treatment alternatives have to be performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_96_18DOI Listing
January 2018

The survival impact of surgical waiting time in patients with resectable pancreatic head cancer.

Ann Hepatobiliary Pancreat Surg 2018 Nov 27;22(4):405-411. Epub 2018 Nov 27.

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Backgrounds/aims: After centralization policy, clinical outcomes have been improved in patients underwent pancreaticoduodenectomy for pancreatic cancer. However, centralization could exacerbate the prolongation of surgical waiting time. This study aims to investigate whether the shorter waiting time correlates with the better survival and to identify the major confounders that influence the association between those. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14701/ahbps.2018.22.4.405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295371PMC
November 2018

Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.

Clin Cancer Res 2018 Dec 26. Epub 2018 Dec 26.

Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania.

The dense stroma underlies the drug resistance of pancreatic ductal adenocarcinoma (PDA) and has motivated the development of stroma-directed drugs. Our objective is to test the concept that dynamic contrast-enhanced (DCE) MRI using FDA-approved contrast media, an imaging method sensitive to the tumor microenvironment, can detect early responses to stroma-directed drug. Imaging studies were performed in three mouse models exhibiting high desmoplastic reactions: the autochthonous PDA in genetically engineered mice (KPC), an orthotopic model in syngeneic mice, and a xenograft model of human PDA in athymic mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2276DOI Listing
December 2018

Multiple brain metastases from pancreatic adenocarcinoma presenting with simultaneous intratumoral hemorrhages: A case report.

World Neurosurg 2018 Dec 19. Epub 2018 Dec 19.

Departments of Neurosurgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

Background: Pancreatic adenocarcinoma rarely metastasizes to the brain, and the clinical features of brain metastasis in such cases remain elusive. To the best of our knowledge, only 21 cases of brain metastasis from pancreatic adenocarcinoma have been previously reported in the English-language literature.

Case Description: One year 4 months before the current admission, a 61-year-old woman was diagnosed with pancreatic adenocarcinoma and began chemotherapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750183285
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2018.12.036DOI Listing
December 2018
9 Reads

Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients.

J Geriatr Oncol 2018 Dec 17. Epub 2018 Dec 17.

Vanderbilt-Ingram Cancer Center, Vanderbilt University, 2220 Pierce Avenue, Nashville, TN 37232, USA. Electronic address:

Objectives: Older patients make up the majority of patients with pancreatic cancer, with a median age of 71 years at diagnosis. However, older patients are underrepresented in clinical trials in pancreatic cancer. This study investigates trends in age distribution of patients enrolled in clinical trials for advanced pancreatic cancer over time, and examines outcomes and toxicity in older patient subgroups from two studies conducted by Eastern Cooperative Oncology Group and American College of Radiology Imaging Network (ECOG-ACRIN) in this disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2018.11.001DOI Listing
December 2018

Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report.

Medicine (Baltimore) 2018 Dec;97(51):e13751

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.

Rationale: Colorectal liver metastasis develops in 50% of patients diagnosed with colorectal cancer, whereas concurrent intrahepatic cholangiocarcinoma (ICC) and colorectal liver metastases is extremely rare.

Patient Concerns: A 72-year-old man was referred to our hospital complaining of abdominal discomfort, diarrhea, and weakness over the last month.

Diagnoses: Colorectal liver metastases concurrent intrahepatic cholangiocarcinoma (ICC). Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005792-201812210-0009
Publisher Site
http://dx.doi.org/10.1097/MD.0000000000013751DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320161PMC
December 2018
2 Reads

Desmoid Fibromatosis Mimicking Metastatic Recurrence After Pancreatectomy for Pancreatic Adenocarcinoma.

Mayo Clin Proc Innov Qual Outcomes 2018 Dec 20;2(4):392-397. Epub 2018 Sep 20.

Department of Radiology, Mayo Clinic, Rochester, MN.

Desmoid fibromatosis is a rare, neoplastic tumor known for its aggressive local invasion and recurrence after surgery. Tumors can occur sporadically or associated with familial adenomatous polyposis. We present 3 cases of desmoid fibromatosis postpancreatectomy for pancreatic adenocarcinoma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S25424548183008
Publisher Site
http://dx.doi.org/10.1016/j.mayocpiqo.2018.07.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260471PMC
December 2018
7 Reads

Familial Pancreatic Ductal Adenocarcinoma.

Am J Pathol 2019 Jan;189(1):36-43

Samuel Bronfman Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:

Pancreatic ductal adenocarcinoma (PDAC), although a rare disease, has a poor prognosis. With 5-year overall survival of 8%, there is a critical need to detect PDAC early or at a premalignant stage. Current screening methods are largely imaging based, but a more focused screening approach based on modifiable and nonmodifiable risk factors may improve the efficacy and likely outcomes of screening. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2018.06.026DOI Listing
January 2019
1 Read

Double primary tumors of the pancreas: A case report.

Medicine (Baltimore) 2018 Dec;97(50):e13616

Department of Radiology, Chungnam National University College of Medicine, Daejeon, South Korea.

Rationale: Adenocarcinoma and neuroendocrine tumors are a very rare combination of double primary pancreas tumor.

Patient Concerns: A Whipple operation was initially performed on a 64-year-old man to remove an adenocarcinoma. Four years after the operation, surveillance- computed tomography revealed abnormal findings of the pancreas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013616DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320203PMC
December 2018
1 Read

Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imaging.

Proteomics Clin Appl 2019 Jan 19;13(1):e1800046. Epub 2018 Dec 19.

Proteopath GmbH, Trier, 54296, Germany.

Purpose: To define proteomic differences between pancreatic ductal adenocarcinoma (pDAC) and pancreatic neuroendocrine tumor (pNET) by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI).

Experimental Design: Ninety-three pDAC and 126 pNET individual tissues are assembled in tissue microarrays and analyzed by MALDI MSI. The cohort is separated in a training (52 pDAC and 83 pNET) and validation set (41 pDAC and 43 pNET). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/prca.201800046DOI Listing
January 2019
1 Read
2.683 Impact Factor

Anaplastic pancreatic cancer diagnosed with endoscopic ultrasound guided fine needle aspiration showing hypervascular tumor: A case report.

Medicine (Baltimore) 2018 Dec;97(49):e13473

Department of Gastroenterology.

Rationale: Pancreatic ductal carcinoma is a hypovascular tumor, and characteristic findings are observed on imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), in most cases.

Patient Concerns: Here we report a case of anaplastic carcinoma of the pancreas (ACP) with characteristics of hypervascular tumor diagnosed by endoscopic ultrasound guided fine needle aspiration (EUS-FNA). A 70-year-old woman was admitted to hospital because of exacerbation of diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310530PMC
December 2018

First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist Ga-NODAGA-MJ9.

EJNMMI Res 2018 Dec 12;8(1):108. Epub 2018 Dec 12.

Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland.

Background: Gastrin-releasing peptide receptor antagonists have promise in theranostics of several highly incident tumours, including prostate and breast. This study presents the first human dosimetry of Ga-NODAGA-MJ9 in the first five consecutive patients with recurrent prostate cancer included in a dual-tracer positron emission tomography (PET) protocol. Five male patients with biochemical relapse of prostate adenocarcinoma underwent four whole-body time-of-flight PET/CT scans within 2 h after tracer injection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-018-0462-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291411PMC
December 2018

First reported case of a collision tumor composed of pancreatic adenocarcinoma and retroperitoneal liposarcoma: a case report.

BMC Cancer 2018 Dec 12;18(1):1243. Epub 2018 Dec 12.

Department of General, Visceral and Tumor Surgery, University Hospital of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.

Background: Collision tumors are rare cases with two different tumor entities growing synchronously. While adenocarcinoma of the pancreas is the most common pancreatic tumor with an incidence of 10 per 100.000, retroperitoneal liposarcoma remains very rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-5151-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292103PMC
December 2018

The importance of pancreatic inflammation in endosonographic diagnostics of solid pancreatic masses.

Med Ultrason 2018 Dec;20(4):427-435

Department of Internal Medicine 1, Friedrich-Alexander-University, Erlangen- Nuremberg, Germany.

Aims: Endosonography (EUS) is one of the main diagnostic tools for the differential diagnosis of pancreatic masses. The aim of our study was to describe the value of this technique in the work-up of solid pancreatic lesions, considering the influence of the morphological evidence of pancreatic inflammation in the diagnostic process.

Material And Methods: Retrospective analysis of prospectively collected data in our tertiary University center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11152/mu-1641DOI Listing
December 2018
1 Read

Preoperative prediction of peripancreatic vein invasion by pancreatic head cancer.

Cancer Imaging 2018 Dec 10;18(1):49. Epub 2018 Dec 10.

Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, China.

Background: Pancreatic adenocarcinoma is often diagnosed at an advanced stage when adjacent vascular invasion is present. Accurate evaluation of presence of vascular invasion can help guide therapy. The aim of this study was to construct a nomogram for preoperative prediction of peripancreatic vein invasion in patients with pancreatic head cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40644-018-0179-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288927PMC
December 2018

Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma.

JCO Precis Oncol 2018 16;2018. Epub 2018 Jan 16.

Department of Medicine, University of California, San Francisco, USA.

Purpose: Desmoplastic stroma is a cardinal feature of primary pancreatic ductal adenocarcinoma (PDAC), but its effects on the biology, prognosis and therapeutic outcomes are not known. We developed an automated method to assess tumor stroma density (TSD) and investigated computed tomography (CT)-correlates of stroma in PDAC.

Patients And Methods: We collected PDAC samples from rapid autopsy and resection series and digitally annotated samples to quantify TSD. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262879PMC
http://dx.doi.org/10.1200/PO.17.00121DOI Listing
January 2018
3 Reads

Role of imaging in the diagnosis of chronic pancreatitis.

Radiologia 2018 Dec 1. Epub 2018 Dec 1.

Servicio de Radiodiagnóstico, Hospital Universitario Doctor Peset, Valencia, España.

Chronic pancreatitis is a progressive fibroinflammatory process in the pancreas that causes permanent structural damage and leads to a deterioration in exocrine and endocrine function. The appearance of flares of acute pancreatitis, pseudocysts, and inflammatory masses all form part of the natural history of this disease. Vascular and / or digestive complications may occur, and patients with chronic pancreatitis have an increased risk of pancreatic adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rx.2018.10.004DOI Listing
December 2018
1 Read

Localized pancreatic Castleman disease presenting with extrahepatic dilatation of bile ducts: A case report and review of published cases.

Int J Surg Case Rep 2019 20;54:28-33. Epub 2018 Nov 20.

Universidade Federal do Vale do São Francisco, Av. José de Sá Maniçoba, S/N - Centro, CEP: 56304-917, Petrolina, PE, Brazil. Electronic address:

Introduction: Castleman disease (CD) is a rare polyclonal lymphoproliferative disorder of unknown etiology, which usually develops in the mediastinum. It can also occur in the cervical, retroperitoneal and axillary regions. Localized pancreatic CD is quite rare [1]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2018.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279997PMC
November 2018
3 Reads

Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas.

HPB (Oxford) 2018 Nov 21. Epub 2018 Nov 21.

Department of Surgery, University Health Network, University of Toronto, Toronto, Canada; University of Toronto, Toronto, Canada. Electronic address:

Background: Stage 3 pancreatic ductal adenocarcinoma (PDAC) is defined by arterial involvement. This study objective was to evaluate outcomes for patients with stage 3 PDAC with potentially reconstructable arterial involvement, considered for neoadjuvant therapy (NAT) and pancreatic resection, and to compare outcomes following arterial (AR) and non-arterial resection (NAR).

Methods: This study included patients from 2009 to 2016 with biopsy-proven stage 3 PDAC who were offered NAT before surgical exploration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hpb.2018.10.004DOI Listing
November 2018
16 Reads

Non-invasive dynamic monitoring initiation and growth of pancreatic tumor in the LSL-Kras;LSL-Trp53;Pdx-1-Cre (KPC) transgenic mouse model.

J Immunol Methods 2019 Feb 20;465:1-6. Epub 2018 Nov 20.

Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA. Electronic address:

The LSL-Kras;LSL-Trp53;Pdx-1-Cre (KPC) mouse is one of the most widely used transgenic models to evaluate tumor characteristics and to develop novel therapies for pancreatic ductal adenocarcinoma (PDAC). There is no report of the effective systemic evaluation of longitudinal KPC tumor imitation and growth. Therefore, we aimed to characterize the initiation and progression of pancreatic cancer in KPC mice using longitudinal multiparametric magnetic resonance imaging (MRI) approaches and overall survival. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00221759183038
Publisher Site
http://dx.doi.org/10.1016/j.jim.2018.11.009DOI Listing
February 2019
11 Reads

Establishment of Slice Cultures as a Tool to Study the Cancer Immune Microenvironment.

Methods Mol Biol 2019 ;1884:283-295

Department of Surgery, University of Washington School of Medicine, Seattle, WA, USA.

Although immunotherapy is currently being widely applied to treat a variety of cancers, there is great heterogeneity in the response to these treatments. Many in the field hypothesize that this may be attributable to the characteristics of each individual tumor immune microenvironment, in addition to systemic immune factors. Therefore, understanding the immune cell microenvironment in a variety of tumors is critically important. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-8885-3_20DOI Listing
January 2019

Tracking Macrophage Infiltration in a Mouse Model of Pancreatic Cancer with the Positron Emission Tomography Tracer [11C]PBR28.

J Surg Res 2018 Dec 7;232:570-577. Epub 2018 Aug 7.

Department of Surgery, University of Michigan, Ann Arbor, Michigan. Electronic address:

Background: The tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) contains abundant immunosuppressive tumor-associated macrophages. High level of infiltration is associated with poor outcome and is thought to represent a major roadblock to lymphocyte-based immunotherapy. Efforts to block macrophage infiltration have been met with some success, but noninvasive means to track tumor-associated macrophagess in PDAC are lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jss.2018.07.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251503PMC
December 2018
1 Read
1.936 Impact Factor